title: Analysis of the recovery of cryopreserved and thawed CD34+ and CD3+ cells collected for hematopoietic transplantation.
abstract: BACKGROUND
  Cryopreservation is often used to store cellular therapies, but little is known about how well CD3+ or CD34+ cells tolerate this process.
  
  
  METHODS
  Viable CD34+ cell recoveries were analyzed from related and unrelated donor granulocyte-colony-stimulating factor (G-CSF)-mobilized peripheral blood stem cell (PBSC) products and viable CD3+ cell recoveries from G-CSF-mobilized and nonmobilized apheresis products from related and unrelated donors. All products were cryopreserved with 5% dimethyl sulfoxide and 6% pentastarch using a controlled-rate freezer and were stored in liquid nitrogen. Related donor products were cryopreserved immediately after collection and unrelated donor products greater than 12 hours postcollection.
  
  
  RESULTS
  The postthaw recovery of CD34+ cells from related donor PBSCs was high (n = 86; 97.5 ± 23.1%) and there was no difference in postthaw CD34+ cell recovery from unrelated donor PBSCs (n = 14; 98.8 ± 37.2%; p = 0.863). In related donor lymphocyte products the postthaw CD3+ cell recovery (n = 48; 90.7 ± 21.4%) was greater than that of unrelated donor products (n = 14; 66.6 ± 35.8%; p = 0.00251). All unrelated donor lymphocyte products were from G-CSF-mobilized products, while most related donor lymphocyte products were from nonmobilized products. A comparison of the CD3+ cell recovery from related donor G-CSF-mobilized products (n = 19; 85.0 ± 29.2%) with that of unrelated donor products found no significant difference (p = 0.137).
  
  
  CONCLUSIONS
  The postthaw recovery of CD34+ cells was high in both related and unrelated donor products, but the recovery of CD3+ cells in unrelated donor G-CSF-mobilized products was lower. G-CSF-mobilized unrelated donor products may contain fewer CD3+ cells than non-G-CSF-exposed products upon thaw and, when indicated, cell doses should be monitored.
authors.affiliation: Cell Processing Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health (NIH), Bethesda, Maryland.
authors.forename: Virginia
authors.initials: V
authors.lastname: Fisher
authors.forename: Hanh
authors.initials: H
authors.lastname: Khuu
authors.forename: Virginia
authors.initials: V
authors.lastname: David-Ocampo
authors.forename: Karen
authors.initials: K
authors.lastname: Byrne
authors.forename: Steven
authors.initials: S
authors.lastname: Pavletic
authors.forename: Michael
authors.initials: M
authors.lastname: Bishop
authors.forename: Daniel H
authors.initials: DH
authors.lastname: Fowler
authors.forename: A John
authors.initials: AJ
authors.lastname: Barrett
authors.forename: David F
authors.initials: DF
authors.lastname: Stroncek
mesh_terms: D018952:Antigens, CD34 / Q000378:metabolism; D001772:Blood Cell Count; D001782:Blood Donors; D001793:Blood Preservation; D001800:Blood Specimen Collection; D017252:CD3 Complex / Q000378:metabolism; D002470:Cell Survival; D015925:Cryopreservation; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000166:cytology* / Q000502:physiology; D006801:Humans; D061349:Unrelated Donors
chemical_list: D018952:Antigens, CD34; D017252:CD3 Complex